References

1. Ng EW, Shima DT, Calias P, Cunningham ET Jr, Guyer DR, A amis AP. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov.2006 Feb;5(2):123-32.

2. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD, Rudge JS.VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11393-8. Epub 2002 Aug 12.

3. Aflibercept, VEGF Trap - Regeneron, VEGF Trap (R1R2), VEGF Trap-Eye. Drugs in R & D. 9(4):261-269, July 1, 2008.

4. Nguyen QD, Shah SM, Hafiz G, et al. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology. 2006;113:1522.e1-1522.e14.

5. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD, Rudge JS.VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11393-8. Epub 2002 Aug 12.

6. Aflibercept, VEGF Trap - Regeneron, VEGF Trap (R1R2), VEGF Trap-Eye. Drugs in R & D. 9(4):261-269, July 1, 2008.

7. Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD) (VIEW 2 ) http://clinicaltrials.gov/ct2/show/NCT00637377?term=vegf+trap+view&rank… Accessed in 28 March 2010.

8. Citation http://www.osnsupersite.com/view.aspx?rid=37693

9. Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (COBALT) http://clinicaltrials.gov/ct2/show/NCT00499590?term=bevasiranib+amd&ran… Accessed 29 March 2010.

10. Interim Results of the phase I, Open-Label, Dose-Escalation Study of Intravitreal siRNA PF-04523655 in Patients With Choroidal Neovascularization Secondary to Exudative Age-Related Macular Degeneration: Safety, Tolerability, and Bioactivity, Quan Dong Nguyen, MD, MSc, Presentation at ARVO 2009 Annual Meeting in Fort Lauderdale.

11. Gomes Dos Santos AL, Bochot A, Fattal E. Intraocular delivery of oligonucleotides. Curr Pharm Biotechnol 2005; 6: 7-15.

12. June 11, 2009 RNAi News; http://siliconinvestor.advfn.com/readmsg.aspx?msgid=25714154.

13. http://www.genomeweb.com/rnai/allergan-drops-development-sirna-rx-amd-p….

14. A phase I, Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) in Subjects With Neovascular Age-Related Macular Degeneration http://clinicaltrials.gov/ct2/show/NCT00569140?term=e10030&rank=1 Accessed in 26 March 2010.

15. Combined Inhibition of Platelet Derived (PDGF) and Vascular Endothelial (VEGF) Growth Factors for the Treatment of Neovascular Age-Related Macular Degeneration (NV-AMD) - Results of a phase I Study; D.S. Boyer, Presentation at ARVO 2009 Annual Meeting in Fort Lauderdale.

16. Citation http://en.wikipedia.org/wiki/Tyrosine_kinase, accessed in 28 March 2010.

17. Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol. 2001;2(3):REVIEWS3005. Epub 2001 Mar 9. Review. PubMed PMID: 11276432; PubMed Central PMCID: PMC138918.

18. Coutts JC, Gallagher JT. Receptors for fibroblast growth factors. Immunol Cell Biol. 1995 Dec;73(6):584-9. Review.

19. Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci. 2001 Mar;114(Pt 5):853-65. Review.

20. Larrivée B, Karsan A. Signaling pathways induced by vascular endothelial growth factor (review). Int J Mol Med. 2000 May;5(5):447-56. Review.

21. Ozaki H, Seo MS, Ozaki K, et al. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am J Pathol 2000;156:697-707.

22. Safety and Efficacy of Oral PTK-787. in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration” (ADVANCE) http://clinicaltrials.gov/ct2/show/NCT00138632 Accessed in 28 March 2010.

23. Chen ZZ, et al. IOVS 2007;48: ARVO 2007 E-Abstract 1469.

24. Doukas J, Mahesh S, Umeda N, Kachi S, Akiyama H, Yokoi K, Cao J, Chen Z, Dellamary L, Tam B, Racanelli-Layton A, Hood J, Martin M, Noronha G, Soll R, Campochiaro PA. Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema. J Cell Physiol. 2008 Jul;216(1):29-37.

25. Palanki MS, Akiyama H, Campochiaro P, Cao J, Chow CP, Dellamary L, Doukas J, Fine R, Gritzen C, Hood JD, Hu S, Kachi S, Kang X, Klebansky B, Kousba A, Lohse D, Mak CC, Martin M, McPherson A, Pathak VP, Renick J, Soll R, Umeda N, Yee S, Yokoi K, Zeng B, Zhu H, Noronha G. Development of prodrug 4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotria zin-7-yl)phenyl benzoate (TG100801): a topically administered therapeutic candidate in clinical trials for the treatment of age-related macular degeneration. J Med Chem. 2008 Mar 27;51(6):1546-59.

26. Open-Label, Pilot Study of TG100801 in Patients With Choroidal Neovascularization Due to AMD. http://clinicaltrials.gov/ct2/show/NCT00509548. Accessed in 29 March 2010.

27. A Study to Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD. http://clinicaltrials.gov/ct2/show/NCT00612456. Accessed in 29 March 2010.

28. A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration. http://clinicaltrials.gov/ct2/show/NCT00090532?term=AG-013958&rank=1 Accessed in 29 March 2010.

29. Phase I Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration (EMERALD) http://clinicaltrials.gov/ct2/show/NCT00766337?term=macusight&rank=1 Accessed in 29 March 2010.

30. Zahn G, Vossmeyer D, Stragies R, Wills M, Wong CG, Löffler KU, Adamis AP, Knolle J. Preclinical evaluation of the novel small-molecule integrin alpha5beta1 inhibitor JSM6427 in monkey and rabbit models of choroidal neovascularization. Arch Ophthalmol. 2009 Oct;127(10):1329-35.

31. Citation http://www.ophthotech.com/products/volociximab/

32. A phase I Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age- Related Macular Degeneration http://clinicaltrials.gov/ct2/show/NCT00782093?term=volociximab&rank=9 Accessed 25 March 2010.

33. Study Evaluating the Safety and Response of Fosbretabulin in Asian Patients With Polypoidal Choroidal Vasculopathy(PCV). http://clinicaltrials.gov/ct2/show/NCT01023295?term=oxigene&rank=1. Accessed 26 March 2010.

34. Heeschen C, Jang JJ, Weis M, Pathak A, Kaji S, Hu RS, Tsao PS, Johnson FL, Cooke JP. Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. Nat Med. 2001 Jul;7(7):833-9.

35. Christopher Heeschen, Michael Weis, Alexandra Aicher, Stefanie Dimmeler, John P. Cooke A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors J. Clin. Invest. 2002; 110(4):527.

36. Arias HR, Richards VE, Ng D, Ghafoori ME, Le V, Mousa SA. Role of non-neuronal nicotinic acetylcholine receptors in angiogenesis. Int J Biochem Cell Biol. 2009 Jul;41(7):1441-51. Epub 2009 Jan 29. Review.

37. Safety and Efficacy of ATG003 in Patients With Wet Age-Related Macular Degeneration (AMD) http://www.clinicaltrials.gov/ct2/show/NCT00414206?term=mecamylamine+am… Accessed in 28 March 2010.

38. Safety and Efficacy of ATG003 in Patients With AMD Receiving Anti-VEGF http://www.clinicaltrials.gov/ct2/show/NCT00607750?term=mecamylamine+am… Accessed in 28 March 2010.

39. Duh EJ, Yang HS, Suzuma I, Miyagi M, Youngman E, Mori K, et al: Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGFinduced migration and growth. Invest Ophthalmol Vis Sci 2002; 43: 821–829.

40. Mori K, Gehlbach P, Ando A, McVey D, Wei L, Campochiaro PA: Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2002; 43: 2428–2434.

41. Imai D, Yoneya S, Gehlbach PL, et al. Intraocular gene transfer of pigment epithelium– derived factor rescues photoreceptors from light-induced cell death. J Cell Physiol 2005;202: 570–578.

42. Campochiaro PA, Nguyen QD, Shah SM, Klein ML, Holz E, Frank RN, et al: Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Hum Gene Ther 2006; 17: 167–176.

43. Rasmussen H, Chu KW, Campochairo P, Gehlbach PL, Haller JA, Handa JT, et al: An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD). Hum Gene Ther 2001; 12: 2029–2032.

44. Clinical Trial in Age-Related Macular Degeneration” - Oral presentation at the American Society for Gene Therapy Annual Meeting, June 2007.

45. “All Trans-Retinoic Acid Regulation of Transgene Expression” - Poster presented at the Association of Research for Vision in Ophthalmology (ARVO) 2006 Annual Meeting, April 2006.

46. Voigt K, Izsvák Z, Ivics Z. Targeted gene insertion for molecular medicine. J Mol Med. 2008 Nov;86(11):1205-19. Epub 2008 Jul 8. Review.

47. Campochiaro PA. Ocular neovascularisation and excessive vascular permeability. Expert Opin Biol Ther. 2004 Sep;4(9):1395-402. Review.

48. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005;308:385-389.

49. Edwards AO, Ritter R 3rd, Abel KJ, Manning A, Panhuysen C, Farrer LA.Complement factor H polymorphism and age-related macular degeneration. Science. 2005;308:421-424.

50. Anderson DH, Mullins RF, Hageman GS, Johnson LV. A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol. 2002 Sep;134(3):411-31.

51. Haines JL, Hauser MA, Schmidt S, et al.Complement factor H variant increases the risk of age-related macular degeneration. Science. 2005;308:419-421.

52. Yates JR, Sepp T, Matharu BK, et al; Genetic Factors in AMD Study Group. Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med. 2007;357:553-561.

53. http://www.potentiapharma.com/about/news.htm#29. Accessed in 29 March 2010.

54. Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD) (ASaP). http://clinicaltrials.gov/ct2/show/NCT00473928?term=pot-4&rank=1. Accessed in 29 March 2010.

55. Schnatbaum K, Locardi E, Scharn D, Richter U, Hawlisch H, Knolle J, Polakowski T. Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92. Epub 2006 Jul 28.

56. Citation http://www.ophthotech.com/products/arc1905/ Accessed in 29 March 2010.

57. Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD) (COMPLETE). http://clinicaltrials.gov/ct2/show/NCT00935883 . Accessed in 30 March 2010.

58. A Study of Strontium90 Beta Radiation With Lucentis to Treat Age-Related Macular Degeneration (CABERNET) http://www.clinicaltrials.gov/ct2/show/NCT00454389?term=CABERNET&rank=1. Accessed in 28 March 2010.

59. Safety Study for Treatment of Wet Macular Degeneration Using the TheraSight(TM) Ocular Brachytherapy System http://www.clinicaltrial.gov/ct2/show/NCT00100087?term=TheraSight&rank=1 Accessed in 28 March 2010.

60. Landa G, Butovsky O, Shoshani J, Schwartz M, Pollack A. Weekly vaccination with Copaxone (glatiramer acetate) as a potential therapy for dry age-related macular degeneration. Curr Eye Res. 2008 Nov;33(11):1011-3.

61. Copaxone in Age Related Macular Degeneration. http://clinicaltrials.gov/ct2/show/NCT00466076. Accessed in 27 March 2010.

62. Stokkermans TJW. Treatment of age-related macular degeneration, Clin Eye Vis Care 2000;12(1):15-35.

63. Mechanism of action. Othera Pharmaceuticals Inc. Web site. http://www.othera.com/technology.html. Accessed October 3, 2007.

64. OT-551 antioxidant eye drops to treat geographic atrophy in age-related macular degeneration. ClinicalTrials.gov Web site. http://www.clinicaltrials.gov/ct/show/NCT00306488?order=1 Accessed March 27, 2010.

65. The OMEGA Study: Use of eye drops to treat geographic atrophy associated with age-related macular degeneration (dry AMD). ClinicalTrials.gov Web site. http://www.clinicaltrials.gov/ct/show/NCT00485394?order=1 Accessed 27 March, 2010.

66. Radu RA, Han Y, Bui TV, et al. Reductions in serum vitamin A arrest accumulation of toxic retinal fluorophores: a potential therapy for treatment of lipofuscin based retinal diseases. Invest Ophthalmol Vis Sci. 2005;46:4393-4401.

67. Study of fenretinide in the treatment of geographic atrophy associated with age-related macular degeneration. ClinicalTrials.gov Web site. http://www.clinicaltrials.gov/ct/show/NCT00429936?order=1. Accessed 28 March 2010.

68. Z Yang. Toll-like receptor 3 and geographic atrophy in age-related macular degeneration N Engl J Med 2008.

69. Kendall, R.L., Wang, G., and Thomas, K.A. (1996). Identification of a Natural Soluble Form of the Vascular Endothelial Growth Factor Receptor, FLT-1, and Its Heterodimerization with KDR. Biochem Biophys Res Commun 226, 324-328.

70. Gehlbach, P., Demetriades, A.M., Yamamoto, S., Deering, T., Xiao, W.H., Duh, E.J., Yang, H.S., Lai, H., Kovesdi, I., Carrion, M., Wei, L., and Campochiaro, P.A. (2003b). Periocular gene transfer of sFlt-1 suppresses ocular neovascularization and vascular endothelial growth factor-induced breakdown of the blood-retinal barrier. Hum Gene Ther 14, 129-141.

71. Honda, M., Sakamoto, T., Ishibashi, T., Inomata, H., andUeno, H. (2000). Experimental subretinal neovascularization is inhibited by adenovirus-mediated soluble VEGF/flt-1 receptor gene transfection: a role of VEGF and possible treatment for SRN in age-related macular degeneration. Gene Ther 7, 978-985.

72. Lai, C.M., Brankov, M., Zaknich, T., Lai, Y.K., Shen, W.Y., Constable, I.J., Kovesdi, I., and Rakoczy, P.E. (2001). Inhibition of angiogenesis by adenovirusmediateds Flt-1 expression in a rat model of corneal neovascularization. Hum Gene Ther 12, 1299-1310.

73. Rota, R., Riccioni, T., Zaccarini, M., Lamartina, S., Gallo, A.D., Fusco, A., Kovesdi, I., Balestrazzi, E., Abeni, D.C., Ali, R.R., and Capogrossi, M.C. (2004). Marked inhibition of retinal neovascularization in ratsfollowing soluble-flt-1 gene transfer. J Gene Med 6, 992-1002.

74. Aiello, L.P., Pierce, E., Foley, E., Takagi, H., Chen, H.,Riddle, L., Ferrara, N., King, G., and Smith, L. (1995a). Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A 92, 10457-10461.

75. Bainbridge, J.W., Mistry, A., De Alwis, M., Paleolog, E., Baker, A., Thrasher, A.J., and Ali, R.R. (2002). Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1. Gene Ther 9, 320 326.

76. Tao W, Wen R, Goddard MB, et al. Encapsulated cell-based delivery of CNTF reduces photoreceptor degeneration in animal models of retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2002;43:3292-3298.

77. A Study of an Encapsulated Cell Technology (ECT) Implant for Patients With Atrophic Macular Degeneration. http://clinicaltrials.gov/ct2/show/NCT00447954?term=neurotech&rank=3. Accessed March , 2010.

78. ECT Technology. Neurotech Web site. http://www.neurotechusa.com/product_tech.asp. Accessed on March, 2010.

79. Pulido JS, Winters JL, Boyer D. Preliminary analysis of the final multicenter investigation of rheopheresis for age related macular degeneration (AMD) trial (MIRA-1) results. Trans Am Ophthalmol Soc. 2006;104:221-231=1.

80. Pulido JS, Multicenter Investigation of Rheopheresis for AMD (MIRA-1) Study Group. Multicenter prospective, randomized, doublemasked, placebo-controlled study of Rheopheresis to treat nonexudative age-related macular degeneration: interim analysis. Trans Am Ophthalmol Soc 2002;100:85-106; discussion 106-7.

81. Rheopheresis Blood Filtration Study for the Treatment of Dry Age-Related Macular Degeneration (AMD). Clinicaltrials.gov, identifier NCT00078221.

82. Safety and Effectiveness Investigation for Dry, Non-Exudative Age Related Macular Degeneration (AMD) Using Rheopheresis (RHEO-AMD) Clinicaltrials.gov, identifier NCT00460967.

83. http://www.retinalphysician.com/article.aspx?article=101092.

84. http://www.nature.com/nrd/journal/v5/n2/full/nrd1955.html.

85. Fialho, Sílvia Ligório and Cunha Júnior, Armando da Silva. Iontoforese no transporte ocular de drogas. Arq. Bras. Oftalmol. [online]. 2004, vol.67, n.5, pp. 839-845. ISSN 0004-2749.